| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL21R |
| Uniprot No | Q9HBE5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-236aa |
| 氨基酸序列 | CPDLVCYTDYLQTVICILEMWNLHPSTLTLTWQDQYEELKDEATSCSLHR SAHNATHATYTCHMDVFHFMADDIFSVNITDQSGNYSQECGSFLLAESIK PAPPFNVTVTFSGQYNISWRSDYEDPAFYMLKGKLQYELQYRNRGDPWAV SPRRKLISVDSRSVSLLPLEFRKDSSYELQVRAGPMPGSSYQGTWSEWSD PVIFQTQSEELKEGWNP |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于IL21R重组蛋白的典型文献摘要(文献标题与内容为模拟概括，具体引用需核实原文)：
1. **《Crystal structure of recombinant human IL-21 receptor in complex with IL-21》**
*作者：Hage, C., et al.*
摘要：通过X射线晶体学解析人源IL21R重组蛋白胞外结构域与IL-21的复合物结构，揭示了受体与配体结合的关键氨基酸位点及信号传导机制。
2. **《Recombinant IL-21 receptor fusion protein attenuates autoimmune disease in murine models》**
*作者：Zhang, Y., et al.*
摘要：构建IL21R-Fc重组融合蛋白，实验证明其可通过竞争性抑制IL-21信号通路，显著减轻小鼠类风湿性关节炎模型的炎症反应和组织损伤。
3. **《Expression and functional characterization of soluble IL-21 receptor in T cell lymphoma therapy》**
*作者：Wang, L., et al.*
摘要：利用哺乳动物细胞表达系统制备可溶性IL21R重组蛋白，体外实验表明其可阻断IL-21介导的T细胞淋巴瘤增殖，提示其潜在抗肿瘤应用价值。
注：实际文献需通过PubMed或Google Scholar检索关键词“IL21R recombinant protein”或“soluble IL-21 receptor”获取。
**Background of IL21R Recombinant Protein**
Interleukin-21 receptor (IL21R) is a cell surface protein belonging to the type I cytokine receptor family, which plays a critical role in modulating immune responses. It forms a heterodimeric complex with the common gamma chain (γc), a shared subunit among receptors for cytokines like IL-2. IL-4. and IL-7. This complex enables high-affinity binding to its ligand, IL-21. initiating downstream signaling pathways such as JAK-STAT, MAPK, and PI3K-AKT. These pathways regulate proliferation, differentiation, and functional activation of immune cells, including T cells, B cells, natural killer (NK) cells, and dendritic cells.
IL21R is particularly notable for its dual role in immunity. It promotes cytotoxic T cell and NK cell activity, enhancing antitumor responses, while also contributing to autoimmune pathologies by supporting plasma cell differentiation and autoantibody production. Dysregulation of IL-21/IL21R signaling is linked to diseases such as rheumatoid arthritis, systemic lupus erythematosus, and certain cancers.
Recombinant IL21R protein is engineered *in vitro* using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications and structural integrity. It typically includes the extracellular domain of IL21R, which can be fused with tags (e.g., Fc or His tags) for purification and detection. This protein is purified via affinity chromatography and validated for functionality through binding assays (e.g., ELISA, surface plasmon resonance) and bioactivity tests involving IL-21-responsive cell lines.
As a therapeutic tool, recombinant IL21R is explored for blocking IL-21 signaling in autoimmune disorders or as a decoy receptor to mitigate excessive inflammation. In cancer research, it serves to study IL-21’s context-dependent pro- or anti-tumor effects. Additionally, it aids in structural studies to map interaction sites for drug development.
Overall, IL21R recombinant protein bridges basic research and translational applications, offering insights into immune regulation and therapeutic targeting. Its clinical potential is under evaluation in preclinical and early-phase trials.
×
